Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2026
|
| Soggetti: | |
| Accesso online: | https://onlinelibrary.wiley.com/doi/10.1111/ped.70366 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- Urinary biomarkers and serum VEGF in preterm infants with retinopathy of prematurity treated with ranibizumab Mitsuhide Nagaoka Taketoshi Yoshida Hidekazu Niimi Akane Honda Seiko Maeno Yayoi Miyazono Satomi Inomata Yukako Kawasaki Kentaro Tamura Kenta Matsumura Pediatrics International Abstract Background and Objective Intravitreal injection of anti‐vascular endothelial growth factor (VEGF) antibodies is widely used to treat retinopathy of prematurity (ROP), yet, its systemic effects remain unclear. In adults, intravitreal anti‐VEGF therapy has been associated with proteinuria and acute kidney injury. This study aimed to evaluate the renal effects of anti‐VEGF antibody (Ranibizumab) by longitudinally measuring urinary biomarkers and serum VEGF levels in preterm infants with ROP. Methods Preterm infants were categorized into two groups based on ROP treatment status: those receiving intravitreal ranibizumab (IVR) (treated group) and age‐matched controls without treatment (nontreated group). Urinary biomarkers, including angiotensinogen, liver‐type fatty acid‐binding protein (L‐FABP), albumin, and podocalyxin, were assessed at three time points: before treatment, and at one and 2 months post‐IVR. Serum VEGF levels were measured 1 month post‐IVR. Results The study included 30 infants in the treated group and 12 in the nontreated group. The mean gestational age and birth weight were 24.9 weeks and 664 g in the treated group, and 26.8 weeks and 845.6 g in the nontreated group. The mean postnatal age at treatment was 68.8 days, with a postmenstrual age of 34.8 weeks. No significant differences were observed in urinary biomarker levels between the groups at one and 2 months posttreatment. Serum VEGF levels were higher in the treated group than in the nontreated group after IVR. Conclusion IVR treatment did not show the sustained renal injury or suppress serum VEGF levels in preterm infants with ROP. 10.1111/ped.70366 http://onlinelibrary.wiley.com/termsAndConditions#vor